Literature DB >> 23665024

Fasudil inhibits ER stress-induced VCAM-1 expression by modulating unfolded protein response in endothelial cells.

Daiji Kawanami1, Keiichiro Matoba, Rina Okada, Masami Tsukamoto, Jun Kinoshita, Sho Ishizawa, Yasushi Kanazawa, Tamotsu Yokota, Kazunori Utsunomiya.   

Abstract

The process of atherosclerosis is affected by interactions among numerous biological pathways. Accumulating evidence shows that endoplasmic reticulum (ER) stress plays a crucial role in the development of atherosclerosis. Rho-kinase is an effector of small GTP-binding protein Rho, and has been implicated as an atherogenic factor. Previous studies demonstrated that fasudil, a specific Rho-kinase inhibitor, exerts a cardioprotective effect by downregulating ER stress signaling. However, the molecular link between ER stress and Rho-kinase in endothelial cells has not been elucidated. In this study, we investigated the mechanisms by which fasudil regulates endothelial inflammation during ER stress. Tunicamycin, an established ER stress inducer, increased vascular cellular adhesion molecule (VCAM)-1 expression in endothelial cells. Intriguingly, fasudil inhibited VCAM-1 induction. From a mechanistic stand point, fasudil inhibited expression of activating transcription factor (ATF)4 and subsequent C/EBP homologous protein (CHOP) induction by tunicamycin. Furthermore, fasudil attenuated tunicamycin-induced phophorylation of p38MAPK that is crucial for the atherogenic response during ER stress. These findings indicate that Rho-kinase regulates ER stress-mediated VCAM-1 induction by ATF4- and p38MAPK-dependent signaling pathways. Rho-kinase inhibition by fasudil would be an important therapeutic approach against atherosclerosis, in particular, under conditions of ER stress.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665024     DOI: 10.1016/j.bbrc.2013.04.091

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.

Authors:  Nibrass Taher Abdali; Awny H Yaseen; Eman Said; Tarek M Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-18       Impact factor: 3.000

2.  Glycated LDL increase VCAM-1 expression and secretion in endothelial cells and promote monocyte adhesion through mechanisms involving endoplasmic reticulum stress.

Authors:  Laura Toma; Gabriela M Sanda; Mariana Deleanu; Camelia S Stancu; Anca V Sima
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

Review 3.  Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.

Authors:  Robert N Mahon; Richard Hafner
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

4.  Proteomic analyses of brain tumor cell lines amidst the unfolded protein response.

Authors:  Jasmina S Redzic; Joe D Gomez; Justin E Hellwinkel; Thomas J Anchordoquy; Michael W Graner
Journal:  Oncotarget       Date:  2016-07-26

5.  ER stress and Rho kinase activation underlie the vasculopathy of CADASIL.

Authors:  Karla B Neves; Adam P Harvey; Fiona Moreton; Augusto C Montezano; Francisco J Rios; Rhéure Alves-Lopes; Aurelie Nguyen Dinh Cat; Paul Rocchicciolli; Christian Delles; Anne Joutel; Keith Muir; Rhian M Touyz
Journal:  JCI Insight       Date:  2019-12-05

6.  78 kDa Glucose-Regulated Protein Attenuates Protein Aggregation and Monocyte Adhesion Induced by Angiotensin II in Vascular Cells.

Authors:  Stephanie Cicalese; Keisuke Okuno; Katherine J Elliott; Tatsuo Kawai; Rosario Scalia; Victor Rizzo; Satoru Eguchi
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

Review 7.  Targeting Redox Imbalance as an Approach for Diabetic Kidney Disease.

Authors:  Keiichiro Matoba; Yusuke Takeda; Yosuke Nagai; Tamotsu Yokota; Kazunori Utsunomiya; Rimei Nishimura
Journal:  Biomedicines       Date:  2020-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.